ESMO: Lilly pads case for third-to-market abemaciclib with more positive breast cancer data
admin 9th September 2017 Uncategorised 0Eli Lilly is gearing up to challenge Pfizer’s Ibrance and Novartis’ Kisqali in HR-positive, HER2-negative breast cancer, and it rolled out more positive data for candidate abemaciclib over the weekend to help it get there.
More: ESMO: Lilly pads case for third-to-market abemaciclib with more positive breast cancer data
Source: fierce